文献速递血栓与止血

利扎布替尼对比安慰剂治疗成人免疫性血小板减少症的安全性与疗效:3期LUNA3研究

Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study.
PubMed 文献 · Blood · 2025-01-01

LUNA3是一项3期研究,在既往接受过治疗的持续性/慢性免疫性血小板减少症成人中,口服利扎布替尼400 mg每日两次(n=133)对比安慰剂(n=69)治疗24周。主要终点持久血小板反应在利扎布替尼组为31例(23%),安慰剂组为0例(P<.0001),所有次要疗效终点均显著优于安慰剂。

要点

  • 持久血小板反应利扎布替尼组31例(23%)vs 安慰剂组0例(P<.0001)。
  • 利扎布替尼使补救治疗使用减少52%(P=.0007),第25周出血评分改善(P=.0006)。
  • 治疗相关不良事件主要为1/2级,1例发生治疗相关3级外周动脉栓塞。

核心结论

  • 在既往多种ITP治疗失败的患者中,利扎布替尼显示快速持久的血小板反应、减少补救用药和出血、改善躯体疲劳,且安全性良好。

研究设计与样本

  • 3期LUNA3研究,在既往接受过治疗的持续性/慢性ITP成人中评估口服利扎布替尼400 mg每日两次(n=133)对比安慰剂(n=69),治疗24周。
  • 基线总体中位年龄47岁,女性63%,中位ITP病程7.7年,28%既往脾切除。

主要发现

  • 总体(N=202)中,利扎布替尼组85例(64%)和安慰剂组22例(32%)在最初12周内达到血小板反应并符合继续治疗资格。
  • 主要终点持久血小板反应(24周中最后12周内至少8周中有至少三分之二的时间血小板计数≥50×10^9/L且未用补救治疗)见于利扎布替尼组31例(23%)vs 安慰剂组0例(P<.0001)。
  • 所有次要疗效终点利扎布替尼均显著优效(P<.05)。
  • 利扎布替尼应答者中位首次血小板反应时间为15天。
  • 利扎布替尼使补救治疗使用显著减少52%(P=.0007),第25周出血评分改善(P=.0006)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rilzabrutinib is a covalent, reversible Bruton tyrosine kinase inhibitor targeting multiple immune thrombocytopenia (ITP)-related mechanisms. The phase 3 LUNA3 study in previously treated adults with persistent/chronic ITP evaluated oral rilzabrutinib 400 mg twice daily (n = 133) vs placebo (n = 69) for 24 weeks. At baseline overall, median age was 47 years, 63% female, 7.7 year median ITP duration, and 28% prior splenectomy. Overall (N = 202), 85 (64%) rilzabrutinib and 22 (32%) placebo patients achieved platelet response (≥50 × 109/L or 30 × 109/L to <50 × 109/L and doubled from baseline) during the first 12 weeks and were eligible to continue. The primary end point, durable platelet response (platelet count ≥50 × 109/L for ≥two-thirds of ≥8 of the last 12 of 24 weeks without rescue therapy), was observed in 31 (23%) rilzabrutinib vs 0 placebo patients (P < .0001). All secondary efficacy end points were significantly superior for rilzabrutinib (P < .05). Median time to first platelet response was 15 days in rilzabrutinib responders. Rilzabrutinib significantly reduced rescue therapy use by 52% (P = .0007) and improved week 25 bleeding scores (P = .0006). Improved physical fatigue was sustained from week 13 (P = .01) through 25 (P = .0003). Treatment-related adverse events were mainly grade 1/2. One rilzabrutinib patient with multiple risk factors had serious treatment-related grade 3 peripheral embolism (lower left leg), and another died from unrelated pneumonia. Rilzabrutinib in patients who failed multiple previous ITP therapies showed rapid and durable platelet response, reduced rescue medication and bleeding, improved physical fatigue, and favorable safety. Trial registration: www.clinicaltrials.gov (#NCT04562766) and www.clinicaltrialsregister.eu (#2020-002063-60).

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kuter DJ, Ghanima W, Cooper N, et al. Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study. Blood. 2025. PMID: 40090011. doi:10.1182/blood.2024027336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。